Trellus Health plc confirmed that clinical research conducted by Trellus Health co-founders Laurie Keefer, PhD, and Marla Dubinsky, MD, has associated the GRITT methodology with significantly lower healthcare utilisation, corticosteroid and opioid use in patients suffering from Inflammatory Bowel Disease . The research, conducted at the Susan and Leonard Feinstein IBD Clinical Center at The Mount Sinai Hospital by Dr. Keefer and her team, identified that use of the GRITT™, which includes the GRITT resilience assessment and personalised treatment methodology, resulted in a 59% increase in resilience amongst study participants, which correlated with a 71% reduction in Emergency Department visits, and a 94% reduction in unplanned hospitalisations. The article also found that the GRITT Program participants showed a 49% decrease in opioid use and a 73% reduction in corticosteroid use at 12 months following the study.

The article concludes that validated methods such as GRITT that simultaneously address mind and body targets, such as resilience evaluation and integrated care management, may improve patient outcomes and are associated with significant reductions in HCU and opioid use. This research reinforces and supplements the positive health outcomes associated with use of the GRITT Methodology presented in an award-winning plenary session at the American College of Gastroenterology 2020 Annual Scientific Meeting, Trellus Health holds the exclusive commercial license of the GRITT methodology from the Icahn School of Medicine at Mount Sinai, part of the Mount Sinai Health System in New York, NY, for IBD and seven major chronic conditions, including heart disease, cancer, kidney disease, diabetes, autoimmune diseases, COPD and Cystic Fibrosis. The Company intends to scale GRITT globally using its proprietary TrellusElevate platform and virtual licensed multidisciplinary care teams that include specialist nurses, behavioral health specialists and registered dietitian nutritionists.